PHIO Projected Dividend Yield

Phio Pharmaceuticals Corp ( NASDAQ : PHIO )

Phio Pharmaceuticals is a biotechnology company whose INTASYL™ self-delivering RNA interference technology platform improves the immune cells in killing tumor cells. Co.'s pipeline includes: PH-762, which is designed to reduce the expression of cell death protein 1; PH-894, which is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells; PH-804, which is designed to target TIGIT, a protein that inhibits the activity of Natural Killer cells; PH-109, which is designed to suppress the connective tissue growth factor protein; and an INTASYL compound that is designed to target CTLA-4, a protein that inhibits the ability of T cells to kill tumor cells.

20 YEAR PERFORMANCE RESULTS